SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 4 Westmount Square, Suite 160,canada
- in****@****era.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- semathera.com
- HQ
- Westmount, Quebec
Semathera Inc Questions
Semathera Inc's website is semathera.com
Semathera Inc's LinkedIn profile is https://ca.linkedin.com/company/semathera-inc
Semathera Inc has
6 employees.
View email and phone details for 6
employees at Semathera Inc.
Semathera Inc's industry is
Biotechnology Research
Semathera Inc's top competitors are
Thryv Therapeutics Inc.,
Cyclenium Pharma Inc.,
Synucure Therapeutics,
Laurent Pharmaceuticals,
Theratechnologies Inc.,
Anasens,
Myx Therapeutics,
Unity Biotechnology,
Cordex Biologics,
Epitopea.
Semathera Inc's support email address is info@semathera.com
Semathera Inc's categories are Biotechnology Research
Semathera Inc's founding year is 2016
